ReviewLangenbeck's archives of surgery2012
Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.
Review in Langenbeck's archives of surgery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Current evidence and future perspectives in the treatment of head and neck vagal paragangliomas: a systematic review.Systematic reviews · 2026Pooled it
- Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis.Clinical endocrinology · 2017Pooled it
- Plasma cells and plasmacytoid features in thyroid lesions.Virchows Archiv : an international journal of pathology · 2026Review
- Paraganglioma of the Head and Neck: A Review.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2023Review
- The Role of the Metabolome and Non-Coding RNA on Pheochromocytomas and Paragangliomas: An Update.Metabolites · 2022Article
- Prognostic Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients With Malignant Pheochromocytoma and Paraganglioma.Frontiers in endocrinology · 2021Article
- Integrative analysis of ceRNA network and DNA methylation associated with gene expression in malignant pheochromocytomas: a study based on The Cancer Genome Atlas.Translational andrology and urology · 2020Article
- Characterization of Malignant Head and Neck Paragangliomas at a Single Institution Across Multiple Decades.JAMA otolaryngology-- head & neck surgery · 2019Article
- Paraganglioma of the testicle: A case presentation and review of the literature.Urology case reports · 2019Article
- Transcriptome Analysis Reveals Significant Differences in Gene Expression of Malignant Pheochromocytoma or Paraganglioma.International journal of endocrinology · 2019Article
- Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.The Journal of clinical endocrinology and metabolism · 2017Article
- Laparoscopic resection of ectopic pheochromocytoma.Intractable & rare diseases research · 2017Article
- Malignancy in Pheochromocytoma or Paraganglioma: Integrative Analysis of 176 Cases in TCGA.Endocrine pathology · 2017Article
- DNA methylation analysis in malignant pheochromocytoma and paraganglioma.Journal of clinical & translational endocrinology · 2017Article
- Peptide receptor radionuclide therapy for metastatic paragangliomas.Medical oncology (Northwood, London, England) · 2016Article
- Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas.Annals of surgery · 2016Article
- MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy.Cellular and molecular life sciences : CMLS · 2015Review
- Current approaches and recent developments in the management of head and neck paragangliomas.Endocrine reviews · 2014Review
- Mutation screening in a Norwegian cohort with pheochromocytoma.Familial cancer · 2013Article
- Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations.British journal of cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMalignant pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare disorders arising from the adrenal gland, from the glomera along parasympathetic nerves or from paraganglia along the sympathetic trunk. According to the WHO classification, malignancy of PCCs and PGLs is defined by the presence of metastases at non-chromaffin sites distant from that of the primary tumor and not by local invasion. The overall prognosis of metastasized PCCs/PGLs is poor. Surgery offers currently the only change of cure. Preferably, the discrimination between malignant and benign PCCs/PGLs should be made preoperatively.
methodsThis review summarizes our current knowledge on how benign and malignant tumors can be distinguished.
conclusionDue to the rarity of malignant PCCs/PGLs and the obvious difficulties in distinguishing benign and malignant PCCs/PGLs, any patient with a PCC/PGL should be treated in a specialized center where a multidisciplinary setting with specialized teams consisting of radiologists, endocrinologist, oncologists, pathologists and surgeons is available. This would also facilitate future studies to address the existing diagnostic and/or therapeutic obstacles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.